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Background: Splenectomy remains a common approach for the management of hypersplenism and portal
hypertension in hepatitis B virus (HBV)-associated cirrhotic patients in China and some other Asian countries. The
effects of antiviral therapy on the survival and occurrence of complications in asplenic HBV-associated cirrhotic
patients are unknown. This study analyzed the effect of antiviral therapy on survival and occurrence of major
complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension.
Results: Of the 57 eligible patients for analysis, 28 patients received nucleos(t)ide analogs (treatment group) for
antiviral treatment after splenectomy, while 29 patients received no antiviral treatment (control group). After a
median of 3 years and 9 months, the overall survival and complication-free survival in the treatment group were
higher though not statistically significant than those in the control group. Multivariate analysis showed that antiviral
treatment was associated with increased but not statistically significant overall survival (hazard ratio (HR): 2.272, 95%
confidence interval (CI): 0.952–5.424, P = 0.064) and the antiviral treatment was significantly associated with
increased complication-free survival of the patients (HR: 7.229, 95% CI: 1.271–41.117, P = 0.026). The
complication-free survival in patients aged ≤ 40 years was higher than that in patients aged > 40 years in the
antiviral treatment patients (P = 0.020).
Conclusions: Antiviral therapy initiating after splenectomy may reduce the incidence of complications and tend to
improve the survival in asplenic HBV-associated cirrhotic patients, especially in younger patients, supporting the use
of antiviral therapy in these patients after splenectomy.
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Hepatitis B virus (HBV) is one of the major causative
agents for the development of chronic hepatitis, cirrhosis
and hepatocellular carcinoma (HCC) [1]. Antiviral therapy
for chronic HBV infection in the immune-active phase
and even end-stage cirrhosis and HCC after hepatectomy* Correspondence: liuzhengwen@medmail.com.cn
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reproduction in any medium, provided the orachieved beneficial effects for the suppression of HBV rep-
lication and reduction of disease progression and occur-
rence of complications [2-8].
Patients with HBV-associated decompensated cirrhosis
usually accompany hypersplenism and portal hyperten-
sion, which may be attributable to the occurrence of fre-
quent secondary infection and upper gastrointestinal
bleeding due to leukopenia and thrombocytopenia and
gastroesophageal varices. This may lead to fatal results
in some cases. Splenectomy alone or in combination
with esophagogastric devascularization is one of the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypertension in cirrhotic patients [9].
Splenectomy is shown to improve the liver function, re-
verse hypersplenism and reduce portal pressure in cir-
rhotic patients [9-13]. On the other hand, however,
splenectomy may compromise the immune response of
cirrhotic patients with chronic HBV infection [14,15].
Therefore, patients after splenectomy represent a sub-
group of special individuals in the cirrhotics. Although
antiviral treatment with nucleoside or nucleotide (nucleos
(t)ide) analogs benefits patients in almost all the disease
situation in HBV infection possibly except those in the im-
mune tolerant phase, the effect of antiviral therapy on cir-
rhotic patients with HBV infection experienced spleen
resection is mostly unknown. The aim of this study, there-
fore, was to explore the effects of antiviral therapy with
nucleos(t)ide analogs after splenectomy on the survival
and occurrence of major complications in patients with
HBV-related cirrhosis.
Methods
Patients and data collection
Consecutive patients who were diagnosed HBV-associated
cirrhosis and underwent splenectomy for hypersplenism
and portal hypertension in the First Affiliated Hospital,
School of Medicine, Xi’an Jiaotong University, from
January 1, 2006 to December 31, 2010 were considered for
inclusion in this retrospective study. Data at splenectomy,
including the demographic, laboratory and clinical data,
were collected from hospital medical records. The accu-
mulated data of the patients after hospital discharge post
splenectomy, including the survival and complications,
were then collected by communication with the patients
or the family members of the patients using the contact
information such as telephone and address and/or by
reviewing the case records for those who revisited the doc-
tor. The data were collected as of July 31, 2011.
All the patients were positive for both hepatitis B surface
antigen (HBsAg) and antibody to hepatitis B core antigen
(anti-HBc). The diagnosis of cirrhosis was established by
clinical history of chronic HBV infection with symptoms
and signs such as hepatic encephalopathy, abnormal liver
function such as hypoalbuminemia, elevated serum total
bilirubin, decreased prothrombin time activity, fluctuation
of alanine aminotransferase (ALT) and aspartate amino-
transferase (AST), and presence of portal hypertension
with ascites and esophageal varices, small liver size, irregu-
lar liver surface, altered echotexture or CT value and
splenomegaly on ultrasonography and/or CT and mag-
netic resonance imaging (MRI). The diagnosis of cirrhosis
was also confirmed by pathological examination of liver
tissue biopsy after surgery in some patients. Patients were
treated by splenectomy with esophagogastric devasculari-
zation according to the severity of esophagogastric varices.To ensure the comparability, patients aged less than
18 years and diagnosed as HCC before splenectomy were
excluded. Patients with infection of other hepatitis viruses
and human immune deficiency virus, autoimmune disor-
ders and other diseases unrelated to HBV infection were
also excluded.
The study was approved by the Ethics Committee of
First Affiliated Hospital, School of Medicine, Xi’an Jiao-
tong University and performed in accordance with Dec-
laration of Helsinki. Informed consent was obtained
from all the patients.
Categorization of antiviral treatment and control patients
During the study period, antiviral therapy was not rou-
tinely recommended for HBV-related cirrhosis patients
and the use of antiviral therapy depended on the recom-
mendation of the doctors and the willingness of the
patients. This facilitated the collection of data from both
patients with and without antiviral treatment. Among all
the patients with HBV-related cirrhosis and underwent
splenectomy during the study period, we retrieved all
the data as described above. Of the patients who had
data eligible for analysis, those who commenced their
antiviral therapy with nucleos(t)ide analogs within 1 week
after splenectomy and the treatment lasted more than
6 months were included as treatment group, and those
who did not initiate antiviral therapy after splenectomy
throughout the study period were categorized as control
group. Patients who received antiviral therapy prior to
splenectomy were excluded in terms of antiviral treat-
ment and control patients.
The survival and occurrence of major complications of
cirrhosis including ascites, hepatic encephalopathy, vari-
ceal hemorrhage, spontaneous bacterial peritonitis,
hepatorenal syndrome, development of HCC and deaths
after splenectomy during the study period were retrieved
and recorded in both the treatment and control groups.
Statistical analysis
Statistical analyses were carried out using a SPSS16.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Continuous variables
were compared using Student’s t-test or Mann–Whitney
U-test as appropriate. Categorical variables were com-
pared with the X2 test. Overall survival was defined as the
date after splenectomy to the date of death of all causes.
Complication-free survival was defined as the date after
splenectomy to the date of occurrence of the major com-
plications. Overall survival and complication-free survival
were analyzed using the Kaplan–Meier method, and the
differences between antiviral therapy-treated patients and
the controls were compared using Log-Rank test. Thirteen
clinical variables including with or without antiviral treat-
ment were selected for univariate and then multivariate
analysis by Cox-regression to identify predictive factors for
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significance was set at P < 0.05.
Results
Background and baseline characteristics
From January 1, 2006 to December 31, 2010, a total of 129
patients with HBV-related cirrhosis underwent splenec-
tomy due to hypersplenism and portal hypertension. Of
these patients, 4 patients were excluded due to the devel-
opment of HCC before splenectomy. Of the remaining
125 patients, 35 patients were not reachable to obtain
complete data due to the change of contact information.
The remaining 90 patients had retrievable data throughout
the study period for analysis. Among these 90 patients, 61
patients used antiviral therapy and 29 patients did not.
One patient used interferon-α and 32 patients had
initiated antiviral treatment before surgery. These 33
patients were excluded in the analysis. Finally, the
remaining 28 patients who commenced their antiviral
therapy within 1 week after splenectomy and continued
the treatment for more than 6 months were included in
the antiviral group (treatment group); the 29 patients who
had their data collected and did not use any antiviral ther-
apy were included in the control group (Figure 1).
The nucleos(t)ide analogs used in the 28 treatment
patients were lamivudine (100 mg/d) in 9, adefovir dipi-
voxil (10 mg/d) in 11, entecavir (0.5 mg/d) in 4, telbivu-
dine (600 mg/d) in 2, and lamivudine in combination with
adefovir dipivoxil in 2 patients. The duration of post-
splenectomy antiviral treatment ranged from 7 months toFigure 1 Flow chart of the study population.5 years and 7 months with a median of 3 years and
9 months. Two patients stopped the antiviral therapy
(lamivudine) 1 year after the initiation of treatment with
no viral breakthrough and occurrence of complication
throughout the study period. The remaining patients had
used the antiviral treatment throughout the study period.
The nucleos(t)ide analogs were safe and all the patients
tolerated well with no severe adverse events reported.
The demographics and clinical characteristics of the
patients in the treatment and control groups before
splenectomy are shown in Table 1. There were no sig-
nificant differences in the age, distribution of sex, Child-
Pugh grade, percentage of HBeAg positivity, HBV DNA
load, white blood cell and platelet count, international
normalized ratio (INR), ALT and AST levels, serum bili-
rubin, and albumin level between the 2 groups of
patients (Table 1).
Comparison of overall survival between patients with and
without antiviral therapy
No death was observed in the treatment group during the
study period. Two patients died in control group. One 54-
year-old male patient died of gastrointestinal bleeding
25 months after splenectomy and another 35-year-old fe-
male patient died of HCC 30 months after the operation.
There was no significant difference of overall survival in
patients given antiviral therapy after splenectomy compared
with those in the control group. The 1-, 3-, and 5-year over-
all survival rates in the treatment group were 100.0%,
100.0%, and 100.0%, respectively; in the control group, the
Table 1 Preoperative demographic and clinical characteristics of the patients in treatment and control groups
Treatment group (n = 28) Control group (n = 29) P
Sex (M:F) 24:4 20:9 0.132
Age [Mean ± SD (range) (years)] 39.75 ± 9.01 (19–54) 42.65 ± 8.56 (23–64) 0.716
Child-Pugh Grade (%) 0.519
A 8 (28.57) 11 (37.93)
B 13(46.43) 14 (48.28)
C 7 (25.00) 4 (13.79)
HBeAg (%) 0.082
Positive 14 (50.00) 8 (27.59)
Negative 14 (50.00) 21 (72.41)
HBV DNA (IU/ml) (%) 0.073
<103 4 (14.29) 13 (44.83)
≥103 -105 10 (35.71) 8 (27.59)
≥105 - 107 12 (42.86) 6 (20.69)
≥107 2 (7.14) 2 (6.89)
White blood cell count (×109/L) 2.70 ± 1.85 3.30 ± 4.06 0.854
Platelet count (×109/L) 38.11 ± 14.53 45.80 ± 26.22 0.648
INR 1.12 ± 0.49 1.23 ± 0.21 0.533
ALT( IU/L) 49.00 ± 22.89 50.20 ± 87.24 0.148
AST( IU/L) 47.23 ± 22.60 50.42 ± 77.47 0.079
Serum bilirubin (μmol/L) 28.58 ± 15.76 21.20 ± 7.19 0.139
Albumin (g/L) 32.63 ± 9.16 35.84 ± 6.14 0.129
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; INR, international normalized ratio; IU, international unit; SD, standard
deviation.
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and 67.9%, respectively (P = 0.230, Figure 2).
Comparison of complication-free survival between
patients with and without antiviral therapy
The complication-free survival rate in the treatment
group was higher than that in the control group al-
though the difference was not significant. The 1-, 3-, and
5-year complication-free survival rates in the treatment
group were 82.6%, 64.8%, and 64.8%, respectively; in the
control group, the 1-, 3-, and 5-year complication-free
survival rates were 88.0%, 50.1%, and 25.0%, respectively
(P = 0.078, Figure 3).
Factors associated with patient overall survival and
complication-free survival
For factors associated with patient overall survival, uni-
variate analysis of the baseline clinical variables revealed
no significant factors that could predict overall survival
(Table 2). After multivariate analysis, the antiviral ther-
apy was associated with increased overall survival al-
though not statistically significant (hazard ratio (HR):
2.272, 95% confidence interval (95% CI): 0.952–5.424,
P = 0.064). Serum AST level (HR: 0.273, 95% CI: 0.082–
0.907, P = 0.034), international normalized ratio (INR)(HR: 0.212, 95% CI: 0.072–0.630, P = 0.005) and HBeAg
status (HR: 4.823, 95% CI: 1.772–13.129, P = 0.002) were
factors associated with overall survival (Table 2).
However, for factors associated with patient
complication-free survival, univariate analysis of the
baseline clinical variables revealed that the antiviral ther-
apy was not significantly associated with complication-
free survival (P = 0.074, Table 3). The age of the patients
at splenectomy was a significant factor (P = 0.004,
Table 3). However, after multivariate analysis, the use of
antiviral therapy was an independent factor associated
with complication-free survival (HR: 7.229, 95% CI:
1.271–41.117, P = 0.026) and the age (HR: 9.264, 95% CI:
1.806–47.528, P = 0.008) remained an independent factor
associated with complication-free survival (Table 3).
When stratifying patients with and without antiviral
treatment according to the age of the patients at splenec-
tomy, complication-free survival rates were improved by
antiviral treatment in both patients aged ≤ 40 years
(Figure 4A) and those aged > 40 years (Figure 4B). For
patients aged ≤ 40 years, the 1-, 3-, and 5-year complica-
tion-free survival rates in the treatment group were all
100.0%, and for those of the patients in the control group
were 100.0%, 85.71%, and 85.71%, respectively (P = 0.080).
The 1-, 3-, and 5-year complication-free survival rates for
Figure 2 Cumulative overall survival plotted using the Kaplan–Meier method and compared using log-rank test. Patients in the
treatment group during the study period had higher overall survival than those in the control group but no statistic significance (P = 0.230).
Figure 3 Cumulative complication-free survival plotted using the Kaplan–Meier method and compared using log-rank test in the
treatment group and the control group. Patients in the treatment group during the study period had higher complication-free survival than
those in the control group with no statistic significance (P = 0.078).
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Table 2 Univariate and multivariate analysis of the overall survival of patients with HBV-related cirrhosis undergoing
splenectomy for hypersplenism and portal hypertension
No. of patients Overall Survival (%) 3 year 5 year Univariate analysis Multivariate analysis P
1 year P HR (95% CI)
Antiviral therapy 0.230 2.272(0.952–5.424) 0.064
Yes 28 100.0 100.0 100.0
No 29 100.0 90.5 67.9
Gender 0.466 0.359(0.097–1.329) 0.125
Men 44 100.0 95.2 81.4
Women 13 100.0 88.9 88.9
Age (years) 0.782 1.513(0.701–3.263) 0.291
≤ 40 26 100.0 94.1 94.1
> 40 31 100.0 94.4 62.9
Child–Pugh grade 0.336 1.061(0.482–2.338) 0.883
A 19 100.0 100.0 100.0
B and C 38 100.0 91.3 76.1
WBC (×109/L) 0.592 0.352(0.109–1.142) 0.082
≥ 3 20 100.0 90.0 45.0
< 3 37 100.0 96.0 96.0
Platelet (×109/L) 0.289 3.951(0.901–17.333) 0.069
≥ 50 13 100.0 85.7 42.9
< 50 44 100.0 96.4 96.4
ALT (IU/L) 0.814 0.990(0.289–3.388) 0.987
< 40 28 100.0 94.7 94.7
≥ 40 29 100.0 93.3 74.6
AST (IU/L) 0.997 0.273(0.082–0.907) 0.034
< 40 27 100.0 94.1 94.1
≥ 40 30 100.0 94.4 78.6
Serum bilirubin (μmol/L) 0.595 1.137(0.262–4.935) 0.864
< 40 49 100.0 93.75 82.0
≥ 40 8 100.0 100.0 100.0
Serum albumin (g/L) 0.397 2.603(0.885–7.657) 0.082
≥ 32 41 100.0 92.5 79.3
< 32 16 100.0 100.0 100.0
INR 0.716 0.212(0.072–0.630) 0.005
< 1.2 25 100.0 92.8 92.8
≥ 1.2 32 100.0 95.2 81.6
HBeAg 0.861 4.823(1.772–13.129) 0.002
Positive 22 100.0 94.1 94.1
Negative 35 100.0 94.4 75.5
HBV DNA (IU/ml) 0.964 0.919(0.349–2.421) 0.864
< 104 26 100.0 100.0 75.0
≥ 104 31 100.0 95.2 95.2
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; INR, international normalized ratio; IU, international unit; WBC, white blood
cell; HR, hazard ratio; 95% CI, 95% confidence interval.
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Table 3 Univariate and multivariate analysis of the complication-free survival of patients with HBV-related cirrhosis
undergoing splenectomy for hypersplenism and portal hypertension
No. of patients Complication-free survival (%) 3 year 5 year Univariate analysis Multivariate analysis P
1 year P HR (95% CI)
Antiviral therapy 0.074 7.229 (1.271–41.117) 0.026
Yes 28 82.6 64.8 64.8
No 29 88.0 50.1 25.0
Gender 0.717 1.023 (0.252–4.159) 0.974
Men 44 80.6 61.3 43.6
Women 13 100.0 55.6 55.6
Age (years) 0.004 9.264 (1.806–47.528) 0.008
≤ 40 26 95.8 78.8 63.0
> 40 31 75.0 37.5 37.5
Child–Pugh grade 0.968 7.848 (0.776–79.315) 0.081
A 19 81.2 54.1 54.1
B and C 38 87.6 57.1 47.6
WBC (×109/L) 0.485 5.505 (0.791–38.301) 0.085
≥ 3 20 94.1 65.9 32.9
< 3 37 80.6 51.6 43.0
Platelet (×109/L) 0.904 0.307 (0.033–2.834) 0.298
≥ 50 13 100.0 71.4 35.7
< 50 44 82.1 52.8 44.0
ALT (IU/L) 0.973 1.959 (0.392–9.794) 0.413
< 40 28 91.7 62.7 62.7
≥ 40 29 79.1 47.5 28.5
AST (IU/L) 0.927 0.791 (0.168–3.726) 0.766
< 40 27 86.3 50.8 50.8
≥ 40 30 84.6 61.1 40.7
Serum bilirubin (μmol/L) 0.468 1.698 (0.120–24.005) 0.695
< 40 49 85.3 53.3 40.0
≥ 40 8 85.8 85.8 85.8
Serum albumin (g/L) 0.688 1.418 (0.276–7.292) 0.676
≥ 32 41 86.11 54.2 38.7
< 32 16 83.3 62.5 62.5
INR 0.516 0.372 (0.043–3.228) 0.369
< 1.2 25 100.0 57.1 57.1
≥ 1.2 32 100.0 71.4 51.0
HBeAg 0.408 0.573 (0.122–2.696) 0.481
Positive 22 80.0 47.0 31.0
Negative 35 89.2 64.4 51.5
HBV DNA (IU/ml) 0.471 1.599 (0.405–6.308) 0.503
< 104 26 81.8 58.4 43.8
≥ 104 31 88.4 53.7 40.3
ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; INR, international normalized ratio; IU, international unit; WBC, white blood
cell; HR, hazard ratio; 95% CI, 95% confidence interval.
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Figure 4 Cumulative complication-free survival plotted using the Kaplan–Meier method and compared using log-rank test in the
patients aged ≤ 40 years (A) and those aged > 40 years (B). In both the patients aged≤ 40 years and those aged > 40 years, antiviral
treatment was associated with a higher complication-free survival but no statistic significance (P = 0.080 and P = 0.546, respectively).
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71.4%, 40.8%, and 40.8%, respectively, and those of the
patients in the control group were 57.1%, 26.0%, and 0%,
respectively (P = 0.546). When stratifying patients aged ≤
40 years and those aged > 40 years according to the anti-
viral treatment or control, the complication-free survival
in the patients aged ≤ 40 years was significantly higher
than those aged > 40 years in the antiviral treatment
patients (P = 0.020, Figure 5A). For the control patients,Figure 5 Cumulative complication-free survival plotted using the Kap
treatment patients (A) and control patients (B) according to age. The
significantly higher than those aged > 40 years in the antiviral treatment pa
survival in the patients aged≤ 40 years was also higher than those aged >the complication-free survival in the patients aged ≤
40 years was also higher than those aged > 40 years but
the difference was not significant (P = 0.091, Figure 5B).
Discussion
Splenectomy may improve the liver function, reverse
hypersplenism and reduce portal pressure and thus de-
crease the occurrence of complications such as infection,
ascites and variceal bleeding in cirrhotic patients [9-13].lan–Meier method and compared using log-rank test in the
complication-free survival in the patients aged≤ 40 years was
tients (P = 0.020). For the control patients, the complication-free
40 years but the difference was not significant (P = 0.091).
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patients [14,15]. Therefore, best practice care is needed
for asplenic patients [16]. For patients with HBV cirrho-
sis after splenectomy for hypersplenism and portal
hypertension, the efficacy and safety of antiviral therapy
have not been well documented although the benefit of
antiviral therapy with nucleos(t)ide analogs has been
demonstrated in most of the disease status of persistent
HBV infection [2-8]. In this study, we showed that the
overall survival rate and complication-free survival rate
in the treatment group was higher than those in the
control group although the difference was not statisti-
cally significant. This may be the result of the insuffi-
cient numbers of patients in our cohort. The univariate
analysis showed no significant factors which may predict
the overall survival but the age of the patients was asso-
ciated with complication-free survival. The multivariate
analysis showed that the antiviral therapy, though not
statistically significant, was associated with increased
overall survival and significantly associated to increased
complication-free survival of the patients. These results
suggest that antiviral therapy also benefits this subgroup
of patients and should be implemented in these patients
after splenectomy. Of course, it is impartial to com-
mence antiviral treatment before surgery for the HBV
cirrhotics. Although antiviral therapy is becoming more
and more common in HBV-associated disease, the
awareness of antiviral treatment should still be empha-
sized because it is always not too late to initiate antiviral
treatment at any stage of chronic HBV infection.
Serum AST level, international normalized ratio (INR)
and HBeAg status were factors associated with overall sur-
vival in multivariate analysis. These parameters are reflec-
tions of the inflammation and synthetic function of the
liver and the characteristics of the virus at splenectomy in
the patients and thus may also affect the disease-
associated survival after splenectomy. Another independ-
ent factor associated to the complication-free survival of
the patients was the age of the patients at splenectomy.
This is consistent with the long-term observation about
the natural history of chronic HBV infection showing that
older age at diagnosis is an important determinant of dis-
ease progression [17,18]. Notably, our results revealed
that, even in the antiviral treatment group, the
complication-free survival rate in younger patients was
higher than that in older patients, suggesting that younger
patients benefit more from the treatment.
There were no serious adverse effects associated with
the use of nucleos(t)ide analogs in the present study.
Understandably, the most significant concern associated
with nucleos(t)ide analogs therapy is the emergence of
resistant mutants [19-21], which may lead to a relapse of
hepatitis and result in fatal liver failure occasionally. In
the present study, we did not determine the emergenceof viral resistant mutants. Lamivudine in combination
with adefovir dipivoxil was administered in 2 patients de
novo to prevent the emergence of resistant mutants tak-
ing into account of their high HBV DNA levels and the
lower rates of resistance and HBV DNA breakthrough as
well as the higher rates of ALT normalization with de
novo combination treatment in chronic hepatitis B
patients [22]. None of the patients with nucleos(t)ide
analogs developed breakthrough hepatitis in our cohort,
probably thanks to the preventive de novo combination,
the uninterrupted administration of the medicine in the
patients and the good compliance in all the patients.
With the advent of new and emerging antiviral agents
such as tenofovir disoproxil and the optimization and
combination of the therapeutics [19,21,23], the emer-
gence of resistant mutants will be well controlled.
One interesting and important issue is the effect of
asplenic status on the seroconversion of HBeAg and/or
HBsAg with antiviral therapy in the HBV patients. Un-
fortunately, we were not able to address this issue be-
cause of the actual difficulty to retrieve the virological
data in most of our patients and to set a comparable
group of HBV-related splenic cirrhotic patients. Theoret-
ically, the asplenia status may reduce the seroconversion
rate because of the absence of the role of spleen in both
innate and adaptive immunity [24-26]. Further studies
are necessary to clarify the effect of splenectomy on the
seroconversion with antiviral therapy in asplenic patients
by comparative observation with splenic patients.
We believe that the antiviral treatment accounts for
the improvement in cumulative complication-free sur-
vival rate and overall survival rate among patients in the
nucleos(t)ide analogs group. However, our study is lim-
ited by the small sample size of patients studied, retro-
spective analysis in design, nonstandardized criteria to
use the nucleos(t)ide analogs, lack of addressing the
seroconversion and the short observation periods. The
statistical power may be insufficient to detect a small
susceptible effect of some factors. Therefore, prospective
studies in larger sample size of patients with standar-
dized criteria to use the nucleos(t)ide analogs and longer
observation periods are needed to clarify the effects of
nucleos(t)ide analogs on asplenic HBV cirrhotic patients.
In fact, due to the rare condition and the lack of stan-
dardized criteria of antiviral therapy for asplenic HBV
cirrhosis patients, prospective randomized trials with
large numbers of patients seem infeasible, and we be-
lieve that our results derived from the retrospective data,
do contribute to the understanding of commencement
of antiviral therapy in this special subgroup of cirrhotic
patients and add novel information for the management
of HBV-associated diseases.
In summary, our present study showed for the first
time to our knowledge that initiation of antiviral therapy
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the occurrence of major complications and tend to im-
prove the survival in asplenic HBV-associated cirrhotic
patients. Multivariate analysis suggests that antiviral
treatment and younger age were factors associated with
reduced occurrence of complications in the asplenic
HBV patients. Younger patients benefit more from the
treatment after splenectomy. Our results therefore sup-
port the use of antiviral therapy in HBV cirrhotic
patients even after splenectomy for hypersplenism and
portal hypertension. Larger prospective studies are war-
ranted to confirm our findings and to address the con-
cerns whether antiviral therapy after splenectomy
improves survival of the patients and affects seroconver-
sion and viral resistance in the asplenic status.
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